FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Related bacterium could create viable TB vax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


The current tuberculosis vaccine--bacille Calmette-Guérin (BCG)--has produced varying efficacy rates worldwide, ranging from 0% to 80%. In a new study published in Nature Medicine, however, researchers have found a promising lead for a new TB vaccine based on a related bacterium.

Mycobacterium smegmatis is in the same bacteria family as TB. Albert Einstein College of Medicine's William Jacobs and his colleagues adapted the bacterium by adding the TB's esx-3 genes to it, creating a new strain called Ikeplus. Mice treated with Ikeplus lived twice as long as those injected with the BCG vaccine on average--135 days versus 65 days.

"This is something we've dreamed about for years, to be able to get longer protection and bactericidal immunity," Jacobs said, according to the BBC. "Ikeplus is different from any other TB vaccine and it's a new tool for the TB arsenal."

Researchers don't know if the vaccine will lead to a more effective human version, and Jacobs expects to continue researching Ikeplus to achieve higher long-term survival rates. In the current study, long-term surviving mice--who lived more than 200 days--only accounted for 20% of the total.

- here's the release
- read the BBC coverage
- check out the Nature Medicine abstract

Related Articles:
Protein could lead to better TB vaccine
Study: Timing of new TB vaccine matters

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Tuberculosis   Tuberculosis Vaccine